MEN1703 is a first-in-class orally available dual PIM and FLT3 kinase inhibitor discovered by Selvita (now Ryvu Therapeutics) and acquired by the Menarini Group at the beginning of 2017.

The molecule has a unique activity profile for its ability of inhibiting both PIM kinase, important for cell cycle regulation, cell survival and tumorigenesis, and FLT3, a kinase involved in the onset and progression of acute myeloid leukemia (AML).

None of the molecules currently in clinical development has this dual activity.

The multicenter, Phase I/II clinical trial DIAMOND-01 is currently ongoing in patients with relapsed /refractory AML.

VISIT OUR CLINICAL TRIALS DATABASE

• Press Release 28/03/2017
• Press Release 06/08/2018
• Press Release 23/05/2019
• Press Release 10/06/2019
• Press Release 09/12/2019
• ASCO Annual Meeting 2019, May 31-June 4, Chicago
  CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia
• The PAGE 2019, 11-19 June, Stockhalm
  Development of a Translational Pharmacokinetic-Biomarker-Efficacy Model in Mouse as a Tool for the Human Therapeutic Dose Estimation
• 24th Congress of EHA, June 13-16, 2019 Amsterdam
  “CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia” 
  
• The 62nd American Society of Hematology Annual Meeting 2019, 5 – 8 December
  CLI24-001 (DIAMOND-01): First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
  
• Press Release 14/05/2020
• 25th Congress of EHA, 11-21 June 2020, virtual meeting
  Results of the dose escalation part of DIAMOND trial (CLI24-001): first in human study of SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.